Sage Mountain Advisors’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Sage Mountain Advisors’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,170	Closed	-$149K	–	374
2022 Q3	$149K	Sell	15,170 -60,330	-80%	-$594K	0.04%	194
2022 Q2	$733K	Sell	75,500 -2,500	-3%	-$24.5K	0.13%	140
2022 Q1	$762K	Sell	78,000 -2,000	-3%	-$19.6K	0.12%	168
2021 Q4	$781K	Hold	80,000	–	–	0.09%	202
2021 Q3	$792K	Sell	80,000 -2,500	-3%	-$25K	0.11%	174
2021 Q2	$829K	Buy	+82,500	New	+$831K	0.14%	150

Other funds holding ORIAU

JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

GAM

Gritstone Asset Management Bethesda, Maryland $93.6M AUM 11.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sage Mountain Advisors's ORIAU Position: Q4 2022 in Review

Sage Mountain Advisors sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q4 2022, closing a stake of 15,170 shares — an estimated $149K sold.

Sage Mountain Advisors first reported a position in ORIAU in Q2 2021 and held it in 6 quarters. The position peaked at $829K in Q2 2021. 6 funds tracked by Wall St. Rank hold ORIAU as of Q4 2022.

Sage Mountain Advisors reported no remaining Orion Biotech Opportunities Corp. Units position as of Q4 2022 after selling out during the quarter.
Sage Mountain Advisors sold 15,170 Orion Biotech Opportunities Corp. Units shares in Q4 2022, an estimated $149K.
Sage Mountain Advisors first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 6 quarters.
Sage Mountain Advisors's Orion Biotech Opportunities Corp. Units position peaked at $829K in Q2 2021.
6 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q4 2022.

Based on Sage Mountain Advisors's 13F filing for Q4 2022, filed 1 Feb 2023.